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Proposing new indicators for glaucoma
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Yuan Bo Liang1,2,5*, Ye Zhang3, David C. Musch4 and Nathan Congdon2
Abstract
Glaucoma is the first leading cause of irreversible blindness worldwide with increasing importance in public health.
Indicators of glaucoma care quality as well as efficiency would benefit public health assessments, but are lacking. We
propose three such indicators. First, the glaucoma coverage rate (GCR), which is the number of people known to have
glaucoma divided by the total number of people with glaucoma as estimated from population-based studies multiplied
by 100%. Second, the glaucoma detection rate (GDR), which is number of newly diagnosed glaucoma patients in one
year divided by the population in a defined area in millions. Third, the glaucoma follow-up adherence rate (GFAR),
calculated as the number of patients with glaucoma who visit eye care provider(s) at least once a year over the total
number of patients with glaucoma in given eye care provider(s) in a specific period. Regularly tracking and reporting
these three indicators may help to improve the healthcare system performance at national or regional levels.
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Background
Assessing healthcare quality and efficiency has become
increasingly important. In the past 20 years, substantial
improvements have been seen in cataract blindness pre-
vention. Indicators of cataract surgical rate (CSR) and
cataract surgery coverage (CSC) played important roles
in evaluating and promoting cataract blindness preven-
tion programs [1]. These indicators provide an evidence
base for evaluating the output of all sectors: government,
non-governmental organizations, and private sectors. As
performance indicators, they measure the extent of the
effort to control cataract blindness and allow for
comparisons between countries and regions. They also
indicate the availability, accessibility, and affordability of
cataract services. Such indicators are not yet available
for glaucoma even though glaucoma is increasingly
important in public health.
Glaucoma is the leading cause of irreversible blind-
ness worldwide. A recent meta-analysis by Tham et al.
estimated that the global pooled prevalence of glau-
coma among persons aged 40–80 years is 3.54% [2]. In
2013, the number of people with glaucoma worldwide
was estimated to be 64.3 million and will increase to
76.0 million in 2020, disproportionately affecting people
residing in Asia and Africa [2]. Glaucoma accounts for
12.3% of blindness worldwide [3]. According to Quigley
et al., bilateral blindness will be present in 5.9 million
people with primary open angle glaucoma (POAG) and
5.3 million people with primary angle closure glaucoma
(PACG) in 2020 [4]. With the reduction in blindness
due to age-related cataract as access to effective treat-
ment increases [5], glaucoma and diabetic retinopathy
will become the two major blindness-causing eye
diseases [6, 7]. Thus, glaucoma is a considerable public
health issue globally.
Glaucoma can be regarded as a group of chronic eye
diseases that have as a common end-point a characteristic
optic neuropathy, which is determined by both structural
changes (optic disk appearance) and functional deficit
(measured by visual field change), with or without an in-
creased intraocular pressure (IOP) [8]. Glaucoma usually
affects both eyes, although they may be affected to varying
degrees. The public health challenge is that if detected
and treated properly with currently available ophthalmic
treatments such as hypotensive eye drops, laser or surgery,
the disease process can be significantly delayed or possibly
prevented. Lack of such treatment is particularly a prob-
lem for underserved populations. Detection and treatment
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of glaucoma fall within the purview of eye care providers,
so it is important to evaluate the effectiveness of eye care
delivery in glaucoma. We suggest the glaucoma coverage
rate (GCR), the glaucoma detection rate (GDR), and the
glaucoma follow-up adherence rate (GFAR) as new indica-
tors for evaluating glaucoma care.
Main text
Glaucoma coverage rate (GCR) and glaucoma detection
rate (GDR)
Even though glaucoma-related blindness is largely pre-
ventable with early detection and appropriate treatment
regimens, many people who have glaucoma are not
diagnosed. For example, in India, studies have found
that 91% of persons with open-angle glaucoma were
unaware, and 20.3% were already blind bilaterally or
unilaterally, respectively, due to glaucoma [9]. In China,
results of the Handan Eye Study showed that over 90%
of participants with primary angle closure (PAC), over
half with PACG and more than 95% of POAG cases
had not previously been diagnosed or treated, while
65.6% of PACG, and 4.5% for POAG were blind in at
least one eye [10, 11]. Even in developed nations, as
many as half of those with glaucoma are unaware that
they have the disease [12–14]. Reasons include inad-
equate screening, unavailability or low utilization of eye
care services, and lack of awareness due to the absence
of symptoms in the early stages of glaucoma.
The GCR could serve as an important index for evalu-
ating glaucoma healthcare. It is calculated by dividing
the number of people in the population with known
glaucoma by the total number of people with glaucoma
as estimated from population-based studies. However,
this parameter can only be obtained through conduct of
or access to results from well-designed population-based
studies. Practically, we would suggest using the number
of patients with newly-detected glaucoma in one year in
a defined region divided by the number of people in that
defined region, which represents the GDR. With increas-
ing improvement in medical care systems in many
countries, the number of detected glaucoma cases can
be accurately tracked [15]. The GDR and GCR will vary
among populations based on public awareness of the
disease, the accessibility and capacity of the regional/na-
tional eye care system, existence of user fees, willingness
to pay and other related factors.
Although population screening for open angle glaucoma
has not been found to be cost effective [16, 17], healthcare
planners can use the GDR to track the impact of other,
more practical methods to increase glaucoma detection,
such as community education [18], screening of targeted
high risk groups (including relatives of known glaucoma
patients) [19] and enhanced clinic-based case finding
through training and incentivizing clinicians to carry out
the complete examinations needed to detect asymptom-
atic glaucoma [20]. With access to estimates of GDR
across nations and regions, focused attention could be
applied to areas with low GDRs and influence those
responsible for allocation of healthcare resources to inter-
vene [21]. Access to a well-established cross-hospital
medical information system would provide an important
resource to track the number of newly-diagnosed cases.
The formula for GCR/GDR would be:
GCR ¼ Number of people with known glaucoma
Total number of patients with glaucoma as
estimated from population‐based studies
 100%
GDR ¼ Number of people with newly‐detected glaucoma in one year
Number of people in a given area in millionsð Þ
Glaucoma follow-up adherence rate (GFAR)
As glaucoma is a chronic eye disease, and IOP is the
only well-proven modifiable risk factor, lifelong ocular
hypotensive medical, laser or surgical treatment is indi-
cated to prevent progression in most cases. Even when
glaucoma is detected and treated, inadequate response
to therapy and/or IOP fluctuation can cause further
damage. This creates the important need for regular
follow-up by eye care professionals to monitor glau-
comatous optic nerve damage and visual field defects,
adjusting therapy as needed [22, 23]. According to
recommended clinical practice, even patients with sus-
pected glaucoma and modest risk for progression should
be seen at least every 12–24 months, whereas patients
with diagnosed glaucoma should have a follow-up visit
every 3–6 months [24].
Poor adherence with recommended glaucoma follow-
up care serves as a major obstacle to proper disease
management. Jin et al. reported follow-up rates at 6, 12
and 48 months after 1186 glaucoma operations in Xian,
China as 68.5, 62.1 and 48.8%, respectively [25]. Main
risk factors for failed follow-up included low annual
income, old age, inability to read, long distance from
hospital, and poor disease awareness. Liu et al. reported
the follow-up rate in cases of PACG in Handan City,
China, at 6, 12 and 48 months after trabeculectomy as
41.1, 21.3 and 13.3%, respectively [26]. They also found
that poor knowledge about glaucoma, rural residence,
and having poor vision were associated with lower
follow-up rates [26]. A recent short-term prospective
study found that poor adherence to recommended
post-trabeculectomy follow-up was associated with
lower education, unawareness of the importance of
follow-up, lack of an accompanying person, low family
annual income, and not requiring removal of scleral
flap sutures postoperatively [27]. The problem of sub-
optimal adherence with both post-operative care and
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medical therapy for glaucoma in developed countries is
also well-documented [28–30]. Additional reasons for
poor follow-up adherence were identified, such as diffi-
culty on the part of the patient or escort to get time off
from work for appointments, long waiting times in the
clinics, unfamiliarity with treatment requirements, lack
of knowledge regarding the permanency of glaucoma-
induced vision loss, cost of examination being too high,
and legal blindness [31, 32].
Adherence to follow-up is an essential component of
effective care for glaucoma. The follow-up adherence
rate can be calculated as the number of follow-up visits
that take place within a defined period of time divided
by the number of expected/planned visits. The latter
number varies greatly due to the differing practice
patterns of clinicians and the stage of glaucoma. For
example, during the early post-operative period, more
frequent visits are needed, whereas less frequent visits
are needed when a patient’s glaucoma status is stable.
Based on a public health perspective, we recommend
GFAR, calculated as the number of patients with glau-
coma who visit eye care provider(s) at least once in a
year’s period divided by the total number of patients
with glaucoma diagnosed in given eye care center(s), as
another essential index for the evaluation of glaucoma
healthcare.
The formula for GFAR would be:
GFAR ¼
Number of glaucoma patients
with at least one visit a year
Number of patients with glaucoma
diagnosed in given eye care center sð Þ
100%
There are some strategies that can be taken within the
healthcare system to improve adherence to follow-up in
glaucoma patients. Suggested measures include: 1) educat-
ing current and in-training eye care providers on proven
communication strategies for improving follow-up; 2)
reducing or eliminating fees for post-operative examina-
tions and consider incentives such as provision of free
medication at postoperative visits, due to the particular
importance of good compliance during this period; 3) pro-
viding visit reminders (e.g., via text or telephone) or a sup-
port network such as a case manager or glaucoma patient
club to help patients adhere to the management require-
ments of their eye condition.
The GDR, GCR, and GFAR, as proposed above, are
sometimes very difficult for a country or region to
estimate, especially so for those with limited healthcare
systems and less accurate data to rely upon. Govern-
ments in most countries are responsible for covering at
least some portion of eye care costs and investment in
low vision rehabilitation and care as well as monitoring
and improving the GDR, GCR, and GFAR are likely to
reduce healthcare costs in the long run. The limitation
of using these indicators is the lack of a threshold value
for judging whether these indicators are reflective of
good or inadequate detection and care of glaucoma
based on limited studies. However, upon measuring
these indicators, they can be used for self-comparison or
cross regional comparison.
Conclusion
In conclusion, from a public health perspective, we need
standard indices to compare and evaluate the level of
glaucoma care across different countries and regions,
with the goal to improve the prevention and treatment
outcome of glaucoma, which is the leading cause of
irreversible blindness. We propose that GDR, GCR, and
GFAR may be particularly useful in this respect.
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